Literature DB >> 22071155

L-arginine supplementation abolishes the blood pressure and endothelin response to chronic increases in plasma sFlt-1 in pregnant rats.

Sydney R Murphy1, Babbette LaMarca, Kathy Cockrell, Marietta Arany, Joey P Granger.   

Abstract

While soluble fms-like tyrosine kinase-1 (sFlt-1) and endothelin-1 (ET-1) have been implicated in the pathogenesis of preeclampsia (PE), the mechanisms whereby increased sFlt-1 leads to enhanced ET-1 production and hypertension remain unclear. It is well documented that nitric oxide (NO) production is reduced in PE; however, whether a reduction in NO synthesis plays a role in increasing ET-1 and blood pressure in response to chronic increases in plasma sFlt-1 remains unclear. The purpose of this study was to determine the role of reduced NO synthesis in the increase in blood pressure and ET-1 in response to sFlt-1 in pregnant rats. sFlt-1 was infused into normal pregnant (NP) Sprague-Dawley rats (3.7 μg·kg(-1)·day(-1) for 6 days beginning on day 13 of gestation) treated with the NO synthase inhibitor N(G)-nitro-L-arginine methyl ester (100 mg/l for 4 days) or supplemented with 2% L-Arg (in drinking water for 6 days beginning on day 15 of gestation). Infusion of sFlt-1 into NP rats significantly elevated mean arterial pressure compared with control NP rats: 116 ± 2 vs. 103 ± 1 mmHg (P < 0.05). NO synthase inhibition had no effect on the blood pressure response in sFlt-1 hypertensive pregnant rats (121 ± 3 vs. 116 ± 2 mmHg), while it significantly increased mean arterial pressure in NP rats (128 ± 4 mmHg, P < 0.05). In addition, NO production was reduced ∼70% in isolated glomeruli from sFlt-1 hypertensive pregnant rats compared with NP rats (P < 0.05). Furthermore, prepro-ET-1 in the renal cortex was increased ∼3.5-fold in sFlt-1 hypertensive pregnant rats compared with NP rats. Supplementation with L-Arg decreased the sFlt-1 hypertension (109 ± 3 mmHg, P < 0.05) but had no effect on the blood pressure response in NP rats (109 ± 3 mmHg) and abolished the enhanced sFlt-1-induced renal cortical prepro-ET expression. In conclusion, a reduction in NO synthesis may play an important role in the enhanced ET-1 production in response to sFlt-1 hypertension in pregnant rats.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22071155      PMCID: PMC3349388          DOI: 10.1152/ajpregu.00319.2011

Source DB:  PubMed          Journal:  Am J Physiol Regul Integr Comp Physiol        ISSN: 0363-6119            Impact factor:   3.619


  31 in total

Review 1.  Preeclampsia: linking placental ischemia with cardiovascular-renal dysfunction.

Authors:  B T Alexander; W A Bennett; R A Khalil; J P Granger
Journal:  News Physiol Sci       Date:  2001-12

Review 2.  Pathophysiology of pregnancy-induced hypertension.

Authors:  J P Granger; B T Alexander; W A Bennett; R A Khalil
Journal:  Am J Hypertens       Date:  2001-06       Impact factor: 2.689

Review 3.  Circulating angiogenic factors in preeclampsia.

Authors:  Richard J Levine; S Ananth Karumanchi
Journal:  Clin Obstet Gynecol       Date:  2005-06       Impact factor: 2.190

Review 4.  Soluble Fms-like tyrosine kinase 1 and endothelial dysfunction in the pathogenesis of preeclampsia.

Authors:  Sharon E Maynard; Shivalingappa Venkatesha; Ravi Thadhani; S Ananth Karumanchi
Journal:  Pediatr Res       Date:  2005-04-06       Impact factor: 3.756

Review 5.  Latest advances in understanding preeclampsia.

Authors:  Christopher W Redman; Ian L Sargent
Journal:  Science       Date:  2005-06-10       Impact factor: 47.728

Review 6.  Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia.

Authors:  Chun Lam; Kee-Hak Lim; S Ananth Karumanchi
Journal:  Hypertension       Date:  2005-10-17       Impact factor: 10.190

Review 7.  Mechanisms of disease: Pre-eclampsia.

Authors:  Marina Noris; Norberto Perico; Giuseppe Remuzzi
Journal:  Nat Clin Pract Nephrol       Date:  2005-12

8.  Extra-placental expression of vascular endothelial growth factor receptor-1, (Flt-1) and soluble Flt-1 (sFlt-1), by peripheral blood mononuclear cells (PBMCs) in normotensive and preeclamptic pregnant women.

Authors:  A Rajakumar; H M Michael; P A Rajakumar; E Shibata; C A Hubel; S Ananth Karumanchi; R Thadhani; M Wolf; G Harger; N Markovic
Journal:  Placenta       Date:  2005-08       Impact factor: 3.481

9.  Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia.

Authors:  Sharon E Maynard; Jiang-Yong Min; Jaime Merchan; Kee-Hak Lim; Jianyi Li; Susanta Mondal; Towia A Libermann; James P Morgan; Frank W Sellke; Isaac E Stillman; Franklin H Epstein; Vikas P Sukhatme; S Ananth Karumanchi
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

Review 10.  Endothelial dysfunction in preeclampsia.

Authors:  J M Roberts
Journal:  Semin Reprod Endocrinol       Date:  1998
View more
  24 in total

1.  Endothelial dysfunction. An important mediator in the pathophysiology of hypertension during pre-eclampsia.

Authors:  B Lamarca
Journal:  Minerva Ginecol       Date:  2012-08

2.  Continued Investigation Into 17-OHPC: Results From the Preclinical RUPP Rat Model of Preeclampsia.

Authors:  Lorena M Amaral; Jessica L Faulkner; Jamil Elfarra; Denise C Cornelius; Mark W Cunningham; Tarek Ibrahim; Venkata Ramana Vaka; Jessica McKenzie; Babbette LaMarca
Journal:  Hypertension       Date:  2017-10-30       Impact factor: 10.190

Review 3.  The emerging role of endothelin-1 in the pathogenesis of pre-eclampsia.

Authors:  Langeza Saleh; Koen Verdonk; Willy Visser; Anton H van den Meiracker; A H Jan Danser
Journal:  Ther Adv Cardiovasc Dis       Date:  2016-01-10

4.  Hypertension, inflammation and T lymphocytes are increased in a rat model of HELLP syndrome.

Authors:  Kedra Wallace; Rachael Morris; Patrick B Kyle; Denise Cornelius; Marie Darby; Jeremy Scott; Janae Moseley; Krystal Chatman; Babbette Lamarca
Journal:  Hypertens Pregnancy       Date:  2014-02       Impact factor: 2.108

5.  Preeclampsia: Linking Placental Ischemia with Maternal Endothelial and Vascular Dysfunction.

Authors:  Bhavisha A Bakrania; Frank T Spradley; Heather A Drummond; Babbette LaMarca; Michael J Ryan; Joey P Granger
Journal:  Compr Physiol       Date:  2020-12-09       Impact factor: 9.090

6.  Nitric oxide synthase-mediated blood pressure regulation in obese melanocortin-4 receptor-deficient pregnant rats.

Authors:  Frank T Spradley; Jennifer M Sasser; Jacqueline B Musall; Jennifer C Sullivan; Joey P Granger
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2016-08-17       Impact factor: 3.619

7.  Reduced uterine perfusion pressure induces hypertension in the pregnant mouse.

Authors:  Suttira Intapad; Junie P Warrington; Frank T Spradley; Ana C Palei; Heather A Drummond; Michael J Ryan; Joey P Granger; Barbara T Alexander
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2014-10-08       Impact factor: 3.619

Review 8.  Pathophysiology and Current Clinical Management of Preeclampsia.

Authors:  Lorena M Amaral; Kedra Wallace; Michelle Owens; Babbette LaMarca
Journal:  Curr Hypertens Rep       Date:  2017-08       Impact factor: 5.369

9.  AT1-AA (Angiotensin II Type 1 Receptor Agonistic Autoantibody) Blockade Prevents Preeclamptic Symptoms in Placental Ischemic Rats.

Authors:  Mark W Cunningham; Javier Castillo; Tarek Ibrahim; Denise C Cornelius; Nathan Campbell; Lorena Amaral; Venkata Ramana Vaka; Nathan Usry; Jan M Williams; Babbette LaMarca
Journal:  Hypertension       Date:  2018-03-19       Impact factor: 10.190

10.  Serelaxin improves the pathophysiology of placental ischemia in the reduced uterine perfusion pressure rat model of preeclampsia.

Authors:  Jose A Santiago-Font; Lorena M Amaral; Jessica Faulkner; Tarek Ibrahim; Venkata Ramana Vaka; Mark W Cunningham; Babbette LaMarca
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2016-09-14       Impact factor: 3.619

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.